Topper James N Insider Trading Activity

Average Profitability
16.09%
Insider Buys Quantity
36
Insider Buys Sum
$21.8M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Topper James N

Biography of Topper James N

No biography is available at this moment.

2025-09-15PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
660
0.0006%
$23.70$15,639+36.11%
2025-09-08PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
1,260
0.0011%
$24.99$31,487+30.85%
2025-08-11PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
471
0.0004%
$23.98$11,294+34.71%
2025-06-25PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
1,260
0.0011%
$18.26$23,012+74.9%
2025-06-24PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
2,520
0.0022%
$18.43$46,454+74.24%
2025-06-16PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
8,584
0.0075%
$19.50$167,381+62.08%
2025-05-21PurchasePhathom Pharmaceuticals, Inc.
PHAT
director
3,780
0.0054%
$3.86$14,609+204.62%
2025-05-14PurchasePhathom Pharmaceuticals, Inc.
PHAT
director
6,300
0.0092%
$3.32$20,919+265.54%
2025-05-13PurchasePhathom Pharmaceuticals, Inc.
PHAT
director
1,120
0.0015%
$3.16$3,543+258.91%
2025-05-12PurchasePhathom Pharmaceuticals, Inc.
PHAT
director
12,601
0.0174%
$3.04$38,301+276.19%
2025-05-09PurchasePhathom Pharmaceuticals, Inc.
PHAT
director
35,602
0.0523%
$3.22$114,616+276.75%
2025-03-26PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
1,135
0.001%
$22.49$25,521+19.9%
2025-03-04PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
4,005
0.0036%
$21.02$84,203+16.7%
2024-03-26PurchaseNewAmsterdam Pharma Company N.V.
NAMS
director
8,429
0.0099%
$21.50$181,224-13.27%
2017-01-31PurchaseAnaptysBio, Inc.
ANAB
800,000
4.6287%
$15.00$12M+59.03%
Total: 15
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.